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Background: Ewing sarcoma is a rare tumor that occurs commonly in the long bones of children or adolescents
that can also arise in soft tissues including the extremities, retroperitoneum, chest wall, and rarely in the liver as
primary sites. We report a case of Ewing sarcoma arising primarily in the liver and, to our knowledge, this is the
fourth reported case of Ewing sarcoma occurring in the liver.
Case presentation: A 27-year-old Japanese woman was admitted with sudden onset right upper abdominal pain.
Clinical examination revealed a multilocular cystic mass consisting of thickened, irregular septa and nodal walls in the
right hepatic lobe. Ultrasound-guided aspiration biopsy of the liver mass showed clusters of small atypical round cells
and the clinical preoperative diagnosis was mucinous cystadenoma of the liver. The patient underwent an extended
right hepatectomy and histopathological findings revealed sheet-like proliferation of small- to medium-sized round
cells. Tumor cells were positive for periodic acid-Schiff reaction and immunoreactive for glycoprotein C99 and gene
NKX2.2, as well as the neuroendocrine markers, CD56 and synaptophysin. EWS-FLI-1 fusion transcript type 1 was
detected by reverse transcriptase polymerase chain reaction. Pathological and molecular analysis confirmed the
diagnosis of Ewing sarcoma arising primarily in the liver and the patient received adjuvant systemic chemotherapy with
vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide. We found no evidence of
recurrence 15 months after completing chemotherapy.
Conclusion: We present an extremely rare case of Ewing sarcoma arising primarily in the liver. To our knowledge, this
is the fourth reported case of Ewing sarcoma occurring in the liver, and the first case with a multilocular cystic liver
mass. Imaging examinations of the other three reported cases showed solid tumors and a diffuse enlarged liver
without mass lesion. Clinicians should consider the possibility of Ewing sarcoma in young patients with a multilocular
cystic mass with thick and/or irregular cyst walls in the liver.
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The Ewing sarcoma family of tumors (EFTs) is a rare en-
tity that includes extraosseous Ewing sarcoma (ES),
primitive neuroectodermal tumor (PNET), Askin tumor,
and atypical ES. ES represents the second most common
primary bone malignancy of children and young adults
[1] and most often arises in the long bones of the ex-
tremities and the pelvic bones [2]. ES rarely occurs in
soft tissues without bone involvement. Common primary
sites of extraosseous ES are the deep soft tissues of the* Correspondence: 1755ozaki@gmail.com
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unless otherwise stated.extremities, retroperitoneum, and chest wall. Extraosseous
ES has also been reported to arise in the kidney [3], uterus
[4], gastrointestinal tract [5], and other visceral organs. To
our knowledge, only three published case reports discuss
ES arising in the liver [6-8]. We report a case of a 27-year-
old female with ES arising in the liver and we review the
literature on extraosseous ES [9].
Case presentation
Case report
A 27-year-old previously healthy woman was transferred
to the emergency department of another hospital in June
2012 because of sudden onset right upper abdominal
pain radiating to her back. She was afebrile and otherhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Color Doppler and contrast-enhanced ultrasonography
showing the multilocular cystic liver mass. Color Doppler
ultrasonography (A) and vascular phase contrast-enhanced
ultrasonography using Sonazoid (92 seconds after bolus injection)
(B) showed the multilocular cystic mass consisted of thickened
irregular septa and nodal walls with blood flow.
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abnormality except for right upper abdominal tenderness.
Enhanced computed tomography (CT) scan revealed a
multilocular cystic mass with enhanced septa, measuring
82 × 66 mm in liver segment 8 (Figure 1). No other lesion
was detected in the CT scan. Ultrasound-guided aspiration
biopsy of the liver mass obtained bloody, mucinous fluid
and bacterial examination of the fluid revealed that it was
sterile. Cytological examination showed clusters of small
round atypical cells with high nuclear/cytoplasm ratio, but
the diagnosis was inconclusive. Blood examination showed
leukocytosis (white blood cells, 13.0 × 103/μL) with normal
transaminase levels and negative hepatitis B surface anti-
gen and antibody. Serum antibodies for hepatitis C virus,
human immunodeficiency virus, and Entamoeba histoly-
tica were negative. Levels of tumor markers of carcinoem-
bryonic antigen and carbohydrate antigen 19–9 were
within normal limits.
The patient was transferred to our hospital three weeks
later. Color Doppler ultrasonography showed the mul-
tilocular cystic mass consisted of thickened irregular septa
and nodal walls with blood flow (Figure 2A). Contrast-
enhanced ultrasonography using Sonazoid (Daiichi-Sankyo,
Tokyo, Japan) described the enhancement of septa and
nodal walls in the vascular phase to the same degree as the
surrounding parenchyma (Figure 2B). Magnetic resonance
imaging was performed but provided no additional in-
formation. We made a presumed diagnosis of mucinous
cystadenoma of the liver based on the imaging studies and
the patient underwent an extended right hepatectomy in
August 2012 (Figure 3) with no postoperative complica-
tions including hepatic failure. R0 resection was achieved.
Histopathological examination revealed monotonous solid
and sheet-like proliferation of small- to medium-sized
round cells with rosette formation (Figure 4A). TumorFigure 1 Enhanced computed tomography scan of the
abdomen showing the multilocular cystic mass. Enhanced
computed tomography scan showing a multilocular cystic mass
(arrow) with enhanced septa, measuring 82 × 66 mm in liver
segment 8.cells were positive for periodic acid-Schiff (PAS) reaction
and immunoreactive for CD99 (Figure 4B), NKX2.2 and
the neuroendocrine markers CD56 and synaptophysin.
EWS-FLI-1 fusion transcript type 1, which is the result of
translocation between exon 7 of the EWSR1 gene onFigure 3 Gross findings of the resected multilocular cystic liver
tumor. The multilocular cystic liver tumor measured 8 × 7 × 6 cm in
size, and consisted of thickened irregular septa and white mural
nodules (arrow).
Figure 4 Microscopic findings of the multilocular cystic liver tumor. Histopathological examination revealed monotonous solid and sheet-like
proliferation of small- to medium-sized round cells with rosette formation (A, H&E, ×100). Immunohistochemical staining for CD99 was positive (B, ×100).
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chromosome 11q24, was detected by reverse transcriptase
real-time polymerase chain reaction. Pathological and mo-
lecular analysis confirmed the diagnosis of Ewing sarcoma.
Postoperative technetium bone scintigraphy and fluoro-
deoxyglucose positron emission tomography revealed no
bone or soft tissue lesion as a primary site of Ewing sar-
coma, no residual lesion in the liver, and no distant metas-
tases. Also, bone marrow aspiration and biopsy revealed
no malignant cells. These findings supported a diagnosis
of localized Ewing sarcoma arising in the liver. The patient
received adjuvant systemic chemotherapy as follows: VDC
(vincristine 1.4 mg/m2, doxorubicin 75 mg/m2, and cyclo-
phosphamide 1200 mg/m2 followed by mesna) alternating
with IE (ifosfamide 1.8 g/m2 with mesna each day for
five days, and etoposide 100 mg/m2 for five days) until
September 2013. We found no evidence of recurrence
15 months after completing chemotherapy.
Discussion
Approximately 80% of EFTs in the pediatric population
arise in bone and < 20% occur in soft tissues, while > 50%
of adult EFTs occur in soft tissues, including the trunk
(14%), retroperitoneum or intra-abdominal tissues (14%),
viscera (8%), and other sites (21%) [10]. Visceral ES is re-
ported to occur in the kidney [3], uterus [4], and gastro-
intestinal tract [5]. Patient characteristics of extraosseous
ES are similar to those of other EFTs, and approximately
80% of patients are younger than 20 years [11].
To our knowledge, only three published case reports dis-
cuss ES arising in the liver [6-8] and because of the rarity of
this entity, little information on the imaging features is avail-
able. Two previous case reports described very large solid
tumors without cystic lesions on CT [6,7], and a third case
report described an enlarged liver without mass lesion on
CT scan [8]; CT scan in our case showed a multilocular cys-
tic lesion. These findings indicate that CT scans in patients
with ES arising in the liver can reveal a polycystic tumor,
solid tumor, or an enlarged liver without mass lesion.
Cystic liver lesions generally represent a heterogeneous
group of diseases. Simple solitary cyst, polycystic disease,parasitic cyst, neoplastic (primary or metastatic) disease,
duct related disease, false cyst, and ciliated foregut cysts
are classified as hepatic cysts [12]. Although most liver
cysts are found incidentally and tend to be benign, some
are associated with malignant disease and thick or ir-
regular cyst walls and/or multilocular cyst space on im-
aging studies are suspicious for malignancy. In our case,
the multilocular cystic liver mass consisted of thickened,
irregular septa and nodal walls and these findings were
highly suspicious for a malignant neoplasm. The pre-
operative clinical diagnosis in our case was mucinous
cystadenoma, which is a rare cystic tumor that occurs
within the liver parenchyma or in the extrahepatic bile
ducts. Differential diagnoses for neoplastic liver cysts are
mucinous cystadenoma, mucinous cystadenocarcinoma,
hepatocellular carcinoma, and metastasis from other
malignant disease [13]. ES is an uncommon differential
diagnosis for cystic liver disease.
ES is described histologically as small, blue, round cells
with hyperchromatic nuclei and scant cytoplasm. The
morphological appearance of ES is similar to that of
other small, blue, round cell tumors, including lymph-
oma, mesenchymal chondrosarcoma, medulloblastoma,
desmoplastic small round cell tumors, and rhabdomyo-
sarcoma. PAS stain is usually positive for ES because of
the presence of abundant glycogen [14] and the vast ma-
jority of ES express strong cell surface glycoprotein
CD99. Our case was also positive for PAS, CD99, vimen-
tin, and NKX2.2 [15]. However, immunohistochemical
findings are not sufficient for diagnosis because these
findings are not specific for ES. Chromosomal transloca-
tion such as t(11;22)(q24;q12) is positive in > 85% of ES
cases and also for PNET [16]. Approximately 10% of ES
cases have other analogous translocations such as t
(21;22)(q22;q12) and t(7;22)(q22;q12) [17,18]; therefore,
cytogenetic and molecular techniques are useful to dis-
tinguish ES/PNET from other tumors.
The standard treatment for extraosseous ES is not estab-
lished because of its rarity; therefore, we used the same
strategy as for osseous ES [19]. Modern treatment guide-
lines recommend primary treatment with multi-agent
Ozaki et al. BMC Cancer  (2015) 15:16 Page 4 of 4chemotherapy followed by local treatment and additional
chemotherapy [20]. ES is highly sensitive to chemotherapy
with vincristine, doxorubicin, cyclophosphamide, ifosfa-
mide and etoposide (VDC/IE). In our case, preoperative
biopsy was not diagnostic and surgical resection was per-
formed as an initial treatment with six cycles of VDC/IE
chemotherapy planned after complete resection. Current
guidelines recommend physical examination, imaging of
the primary site and chest, complete blood count, and
other laboratory studies every 2–3 months for 24 months,
with increasing testing intervals after 24 months and an-
nually after five years [20].
Conclusions
To our knowledge, this is the fourth reported case of
Ewing sarcoma occurring in the liver, and the first case
with a multilocular cystic liver mass. Imaging examina-
tions of the other three reported cases showed solid tu-
mors and a diffusely enlarged liver without a mass lesion.
Clinicians should consider the possibility of ES in young
patients with a multilocular cystic liver mass with thick
and/or irregular cyst walls.
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